LivaNova PLC

Company Overview

LivaNiova, a U.K.-based medical technology company, offers innovative solutions for the head and heart. It designs, builds and commercializes novel medical technologies for better patient improvements. The company operates through three reportable segments: cardiopulmonary, neuromodulation and advanced circulatory support (ACS). It offers a wide range of product portfolios and pipelines, including cardiopulmonary, difficult-to-treat depression, drug-resistant epilepsy and obstructive sleep apnea.

It employs 2,900 employees and commercializes its medical devices in over 100 countries.

Financial Highlights (FY 2024)

Company's Business Segments

• Cardiopulmonary : LivaNova’s Cardiopulmonary segment is engaged in the Design, Development, Manufacture, Marketing, and Selling of Cardiopulmonary products, including HLMs, Oxygenators, Autotransfusion systems, Perfusion tubing systems, Cannulae. It includes the Essenz Perfusion System, the Company’s next-generation HLM with an embedded patient monitor for tailored patient care strategies and sensing technology for data-driven decision-making during CPB procedures.
• Neuromodulation : LivaNova’s Neuromodulation segment is engaged in the Design, Development, Manufacture, Marketing, selling of devices that deliver Neuromodulation therapy for treating DRE DTD. LivaNova’s principal Neuromodulation product, the VNS Therapy System, consists of an Implantable pulse generator, Connective lead that stimulates the vagus nerve; Surgical equipment to assist with the Implant procedure, Equipment, Instruction manuals enabling a treating physician to set parameters for a Patient’s pulse generator, for Epilepsy, magnets to suspend or induce nerve stimulation manually.
• Advanced Circulatory Support : LivaNova’s ACS segment was engaged in the Design, Development, Manufacture, Marketing, Selling of temporary life support products. ACS’s products, which comprise the LifeSPARC, Hemolung systems, Standalone cannulae, Accessories, including ProtekDuo and Transseptal (TandemHeart) cannulae, Simplify temporary extracorporeal cardiopulmonary life support solutions for critically ill patients.
• Other Revenue : Other revenue primarily includes rental income not allocated to segments. For the year ended December 31, 2021, other revenue includes the net revenue of the Company’s Heart Valve business, which was divested on June 1, 2021.